GGrantIndex
Sort

4,870 grants matching glp 1

A Novel Myeloperoxidase Inhibitor for Treating Multiple Sclerosis

$285,790
Stephen Naylor · Reneurogen, Llc · R43 · FY2018 · NS

Novel Long Acting rhTSH Superagonist Analogs for Improved Diagnostic Imaging, Thyroglobulin Stimulation and Therapy of Thyroid Cancer.

$285,070
Bruce Dale Weintraub · Trophogen, Inc. · R44 · FY2018 · CA

Product Development and Manufacturing Core

$284,979
Becky L Rivoire Phd · Colorado State University · U54 · FY2011 · AI

Cyclic Orynotides for Systemic MDR Candidiasis

$284,978
Dat Quang Tran · Oryn Therapeutics, Llc · R44 · FY2019 · AI

Central Viscerosensory Circuits-Structure and Function

$284,376
Linda M Rinaman · University Of Pittsburgh At Pittsburgh · R01 · FY2006 · MH

03-DK-0245 (Effect of AC2993 (synthetic exendin-4) on pancreatic islet function)

$284,071
David Harlan · National Institute Of Diabetes And Digestive And Kidney Diseases · Z01 · FY2008 · DK

Osteopontin-targeted therapy for primary CNS lymphoma

$283,986
John A Copland · Modulation Therapeutics, Inc. · R41 · FY2017 · CA

SmartInsulin Stability, Process Development, Assay Validation and GMP Manufacturi

$283,515
Todd C Zion · Smartcells, Inc. · R44 · FY2007 · DK

Sex-specific factors, inflammation and vascular health across the lifespan in women living with HIV

$283,500
Allison G Hays · Johns Hopkins University · R35 · FY2024 · HL

Biomarker Developmental Unit

$283,024
Cecilia C Yeung · Fred Hutchinson Cancer Center · U2C · FY2022 · CA

Bisphenol A and the Metabolic Syndrome: Focus on Adipose Tissue Functions

$282,600
Nira Ben-Jonathan · University Of Cincinnati · U01 · FY2012 · ES

Metabolic effects of non-nutritive sweeteners

$281,855
Kristina Rother · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2013 · DK

Sex-specific factors, inflammation and vascular health across the lifespan in women living with HIV

$281,116
Allison G Hays · Johns Hopkins University · R35 · FY2025 · HL

Pediatric Type 1 Diabetes: Intervention Trials With Glucagon Suppressors

$280,292
Rubina A Heptulla · Albert Einstein College Of Medicine · R01 · FY2010 · DK

L-type Ca2+ channel modulation of beta cell function

$280,238
Gregory Howard Hockerman · Purdue University · R01 · FY2011 · DK

ROLE OF PRESENILIN IN NOTCH AND APP MATURATION

$280,170
Washington University · R01 · FY2002 · AG

Novel peptide therapeutics to treat cystic fibrosis-related diabetes

$280,122
Robert Schotzinger · Eldec Pharmaceuticals, Inc. · R42 · FY2025 · DK

Rodent pancreatic islet biology in health and disease

$279,534
David Harlan · National Institute Of Diabetes And Digestive And Kidney Diseases · Z01 · FY2008 · DK

Inpatient and outpatient infrastructure for T1DM clinical protocols

$279,534
David Harlan · National Institute Of Diabetes And Digestive And Kidney Diseases · Z01 · FY2008 · DK

L-type Ca2+ channel modulation of beta cell function

$279,409
Gregory Howard Hockerman · Purdue University · R01 · FY2012 · DK

Novel SCD1 inhibitors for treatment of cancer

$279,000
Lori Hazlehurst · Modulation Therapeutics, Inc. · R41 · FY2016 · CA

Sleep deprivation and energy balance

$278,981
Marie-Pierre St-Onge · St. Luke'S-Roosevelt Inst For Hlth Scis · R01 · FY2009 · HL

Therapeutic targets in African-American youth with type 2 diabetes

$278,804
Stephanie Therese Chung · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2025 · DK

PROLIFERATIVE VS MEIOTIC FATE DECISION IN C. ELEGANS

$278,692
Tim B. Schedl · Washington University · R01 · FY2013 · GM

REPRESSIVE HISTONE AND DNA METHYLATION IN RODENT DEPRESSION MODELS

$278,583
Eric J Nestler · Icahn School Of Medicine At Mount Sinai · P50 · FY2013 · MH